Drugs & Targets FDA clears IND for Zymeworks’ antibody drug conjugate ZW191 July 26, 2024Vol.50 No.30
Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.” July 19, 2024Vol.50 No.29By Jacquelyn Cobb
Drugs & Targets FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC July 12, 2024Vol.50 No.28
JudiciaryNews Analysis Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care July 05, 2024Vol.50 No.27By Matthew Bin Han Ong
Conversation with The Cancer Letter Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside July 05, 2024Vol.50 No.27By Matthew Bin Han Ong
Drugs & Targets FDA grants Fast Track designation to Syncromune Inc. for drug-device combo for solid tumors in mCRPC July 05, 2024Vol.50 No.27
White House At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials June 28, 2024Vol.50 No.26By McKenzie Prillaman
Clinical Roundup FDA guidance provides new details on diversity action plans for clinical studies June 28, 2024Vol.50 No.26
Cancer History ProjectFree Remembering the day 22 years ago when ODAC debated the Iressa quandary June 21, 2024Vol.50 No.25By Paul Goldberg
